Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 6, 2008, Pages 1362-1368

  Masquelier, Bernard ^a   Assoumou, K L ^b,c   Descamps, D ^d   Bocket, L ^e   Cottalorda, J ^f   Ruffault, A ^g   Marcelin, A G ^h   Morand Joubert, L ⁱ   Tamalet, C ^j   Charpentier, C ^k   Peytavin, G ^d   Antoun, Z ^l   Brun Vezinet F ^d   Costagliola, D ^b,c  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d BICHAT HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF NICE   (France)

^g RENNES UNIVERSITY HOSPITAL   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ Section of Radiology   (France)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l Glaxo Smith Kline Laboratories   (France)

more..

Author keywords

Genotype; HIV 1 drug resistance; Protease inhibitor

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; SAQUINAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTANT; MUTATIONAL ANALYSIS; RNA VIRUS; SCORING SYSTEM; TREATMENT OUTCOME; VIRUS MUTATION; WILD TYPE;

ADULT; AMINO ACID SUBSTITUTION; CARBAMATES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PHOSPHORIC ACID ESTERS; RITONAVIR; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD;

EID: 44449177782     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn127     Document Type: Article

References (21)

1. Hirsch MS, Brun-Vezinet F, Clotet B et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37: 113-28.
2. Eron J Jr, Yeni P, Gathe J Jr et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial. Lancet 2006; 368: 476-82.
3. Maguire M, Shortino D, Klein A et al. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: Selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 2002; 46: 731-8.
4. MacManus S, Yates PJ, Elston RC et al. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: Absence of protease resistance at 48 weeks. AIDS 2004; 18: 651-5.
5. Ross L, Vavro C, Wine B et al. Fosamprenavir clinical study meta-analysis in ART-naive subjects: Rare occurrence of virologic failure and selection of protease-associated mutations. HIV Clin Trials 2006; 7: 334-8.
6. Quercia R, Garnier E, Ferre V et al. Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: Virological and immunological response in two years follow-up. HIV Clin Trials 2005; 6: 73-80.
7. Pellegrin I, Breilh D, Coureau G et al. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir/ritonavir-based regimens in antiretroviral-experienced patients (Zephir study). Antimicrob Agents Chemother 2007; 51: 1473-80.
8. Lamotte C, Peytavin G, Farinotti R. Determination of nelfinavir, a potent HIV protease inhibitor, and its active metabolite M8 in human plasma by high-performance liquid chromatography with photodiode-array detection. J Chromatogr B Biomed Sci Appl 1999; 735: 159-70.
9. Flandre P, Marcelin AG, Pavie J et al. Comparison of tests and procedures to build clinically relevant genotypic scores: Application to the Jaguar study. Antivir Ther 2005; 10: 479-87.
10. Brun-Vezinet F, Descamps D, Ruffault A et al. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 2003; 17: 1795-802.
11. Masquelier B, Tamalet C, Montes B et al. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther 2004; 9: 315-23.
12. Vora S, Marcelin A, Günthard H et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS 2006; 20: 35-40.
13. Zachary KC, Hanna GJ, D'Aquila RT. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo. Clin Infect Dis 2001; 33: 2075-7.
14. Ziermann R, Limoli K, Das K et al. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol 2000; 74: 4414-9.
15. Hicks CB, Cahn P, Cooper DA et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet 2006; 368: 466-75.
16. Katlama C, Esposito R, Gatell JM et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21: 395-402.
17. Cooper D, Gatell JM, Rockstroh J et al. Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 105aLB, p. 103. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
18. Steigbigel R, Kumar P, Eron J et al. Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 105bLB, p. 103. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
19. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. In: Abstracts of the Eleventh Conference 2004. Abstract 51, p. 95. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
20. Marcelin AG, Flandre P, Molina J et al. Genotypic analysis of the virological rsponse to fosamprenavir/ritonavir in clinical trials: Context and Triad. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 608, p. 290. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
21. Alvarez M, Chueca N, Reina G et al. Development of a genotypic score for the interpretation of resistance to fosamprenavir/ritonavir. In: Abstracts of the Fifth European HIV Drug Resistance Workshop, Cascais, Portugal, 2007. Abstract 102, p. 93. Reviews in Antiviral Therapy, Vol. 2, Utrecht, The Netherlands.